Immunohistochemically detectable bcl-2 expression in colorectal carcinoma

Correlation with tumour stage and patient survival

D. Ofner, K. Riehemann, H. Maier, B. Riedmann, H. Nehoda, M. Totsch, W. Bocker, B. Jasani, K. W. Schmid

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2 proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2 staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification, lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not,associated with prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104 cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5% of bcl-2-positive cells were found in 25, 5-50% in 17 and more than 50% in five cases. The extent of bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P <0.05), decreasing lymphocytic infiltration (P <0.05) and chance of poor clinical outcome (P <0.05), but not with worsening of Dukes stages. In multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic parameter with Dukes' classification as stratification factor (P <0.001). Although the biological functions of bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping of colorectal carcinoma may contribute in future to the clinical management of these patients.

Original languageEnglish
Pages (from-to)981-985
Number of pages5
JournalBritish Journal of Cancer
Volume72
Issue number4
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Oncogene Proteins
Survival
Neoplasms
bcl-2 Genes
Mitochondrial Membranes
Proportional Hazards Models
Cell Death
Multivariate Analysis
Confidence Intervals
Apoptosis
Staining and Labeling
Proteins

Keywords

  • bcl-2
  • Colorectal cancer
  • Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ofner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Totsch, M., ... Schmid, K. W. (1995). Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: Correlation with tumour stage and patient survival. British Journal of Cancer, 72(4), 981-985.

Immunohistochemically detectable bcl-2 expression in colorectal carcinoma : Correlation with tumour stage and patient survival. / Ofner, D.; Riehemann, K.; Maier, H.; Riedmann, B.; Nehoda, H.; Totsch, M.; Bocker, W.; Jasani, B.; Schmid, K. W.

In: British Journal of Cancer, Vol. 72, No. 4, 1995, p. 981-985.

Research output: Contribution to journalArticle

Ofner, D, Riehemann, K, Maier, H, Riedmann, B, Nehoda, H, Totsch, M, Bocker, W, Jasani, B & Schmid, KW 1995, 'Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: Correlation with tumour stage and patient survival', British Journal of Cancer, vol. 72, no. 4, pp. 981-985.
Ofner, D. ; Riehemann, K. ; Maier, H. ; Riedmann, B. ; Nehoda, H. ; Totsch, M. ; Bocker, W. ; Jasani, B. ; Schmid, K. W. / Immunohistochemically detectable bcl-2 expression in colorectal carcinoma : Correlation with tumour stage and patient survival. In: British Journal of Cancer. 1995 ; Vol. 72, No. 4. pp. 981-985.
@article{2f7f671f4a134bfdb8a68d8ca3940265,
title = "Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: Correlation with tumour stage and patient survival",
abstract = "The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2 proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2 staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification, lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not,associated with prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104 cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5{\%} of bcl-2-positive cells were found in 25, 5-50{\%} in 17 and more than 50{\%} in five cases. The extent of bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P <0.05), decreasing lymphocytic infiltration (P <0.05) and chance of poor clinical outcome (P <0.05), but not with worsening of Dukes stages. In multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic parameter with Dukes' classification as stratification factor (P <0.001). Although the biological functions of bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping of colorectal carcinoma may contribute in future to the clinical management of these patients.",
keywords = "bcl-2, Colorectal cancer, Immunohistochemistry",
author = "D. Ofner and K. Riehemann and H. Maier and B. Riedmann and H. Nehoda and M. Totsch and W. Bocker and B. Jasani and Schmid, {K. W.}",
year = "1995",
language = "English",
volume = "72",
pages = "981--985",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Immunohistochemically detectable bcl-2 expression in colorectal carcinoma

T2 - Correlation with tumour stage and patient survival

AU - Ofner, D.

AU - Riehemann, K.

AU - Maier, H.

AU - Riedmann, B.

AU - Nehoda, H.

AU - Totsch, M.

AU - Bocker, W.

AU - Jasani, B.

AU - Schmid, K. W.

PY - 1995

Y1 - 1995

N2 - The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2 proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2 staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification, lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not,associated with prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104 cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5% of bcl-2-positive cells were found in 25, 5-50% in 17 and more than 50% in five cases. The extent of bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P <0.05), decreasing lymphocytic infiltration (P <0.05) and chance of poor clinical outcome (P <0.05), but not with worsening of Dukes stages. In multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic parameter with Dukes' classification as stratification factor (P <0.001). Although the biological functions of bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping of colorectal carcinoma may contribute in future to the clinical management of these patients.

AB - The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2 proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2 staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification, lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not,associated with prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104 cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5% of bcl-2-positive cells were found in 25, 5-50% in 17 and more than 50% in five cases. The extent of bcl-2 expression by tumour cells decreased significantly with respect to increasing tumour size (P <0.05), decreasing lymphocytic infiltration (P <0.05) and chance of poor clinical outcome (P <0.05), but not with worsening of Dukes stages. In multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic parameter with Dukes' classification as stratification factor (P <0.001). Although the biological functions of bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping of colorectal carcinoma may contribute in future to the clinical management of these patients.

KW - bcl-2

KW - Colorectal cancer

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=0028871326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028871326&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 981

EP - 985

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -